BioKangtai: 20-Valent Pneumococcal Vaccine Enters Phase II Clinical Trial

BioKangtai’s 20-valent pneumococcal conjugate vaccine has officially entered Phase II clinical trials. This vaccine is designed for infants and children aged 2 months to 5 years, aiming to prevent infections caused by 20 serotypes of pneumococcus. The Phase II trial will assess its safety and immunogenicity in this age group.

BioKangtai’s progress in this area not only strengthens its position in the global vaccine market, but also has the potential to significantly improve child health outcomes worldwide. BioKangtai looks forward to sharing more updates as the clinical trial progresses.